Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria, Vivax

Interventions

DRUG: Tafenoquine 300mg
DRUG: Tafenoquine 600mg
DRUG: Tafenoquine 1200mg
DRUG: moxifloxacin
DRUG: Placebo for Tafenoquine
DRUG: Placebo for moxifloxaxin

Sponsor

GlaxoSmithKline